|Year : 2021 | Volume
| Issue : 2 | Page : 102-106
The correlation of e-cadherin expression with the modified gleason score and the grade group of prostatic adenocarcinoma
Sakar Azad Hayder1, Alaa Hani Raziq2
1 Department of Pathology, Erbil Health Directorate, Erbil, Iraq
2 Department of Pathology, College of Medicine, University of Duhok, Duhok, Iraq
|Date of Submission||15-Jan-2021|
|Date of Acceptance||07-Feb-2021|
|Date of Web Publication||26-Jun-2021|
Sakar Azad Hayder
Erbil Health Directorate, Erbil
Source of Support: None, Conflict of Interest: None
Background: E-cadherin is a cell adhesion molecule, its downregulation is associated with poorly differentiated tumors in many organs, and its loss is associated with adverse behavior of many tumors. Objectives: This study aims to find a correlation between E-cadherin status, the Grade Group, and the modified Gleason score in core biopsies obtained from prostatic carcinoma. Materials and Methods: This study is a retrospective and prospective cross-sectional study that was conducted on (50) paraffin blocks obtained from core biopsies of prostatic carcinoma. E-cadherin status was correlated with the Grade Group and the modified Gleason score. The E-cadherin staining pattern was also examined for its correlation with perineural invasion. Chi-square was used to determine the correlation between E-cadherin staining pattern on the one hand and the modified Gleason score, Grade Group, and perineural invasion on the other hand and P < 0.5% was considered as significant. Results: Only six patients (12%) fall in Grade Group 1 and according to the modified Gleason score, most patients had high scores. Regarding E-cadherin expression, 24 cases (48%) had aberrant E-cadherin expression, while the rest 26 cases (52%) had a complete strong membranous expression. Statistically, there was a significant correlation between aberrant E-cadherin expression and increasing grade according to the modified Gleason score and Grade Group with P values of 0.032% and 0.022%, respectively. In 24 patients (48%), perineural invasion was detected half of them had aberrant E-cadherin expression which was statistically notsignificant when both the parameters (perineural invasion and aberrant E-cadherin expression) are tested against the modified Gleason score and the Grade Group (P = 0.71%). Conclusion: Aberrant E-cadherin expression is associated with increasing modified Gleason score and Grade Group but has no significant correlation with perineural invasion.
Keywords: E-cadherin, Grade Group, modified Gleason score, prostate
|How to cite this article:|
Hayder SA, Raziq AH. The correlation of e-cadherin expression with the modified gleason score and the grade group of prostatic adenocarcinoma. Med J Babylon 2021;18:102-6
|How to cite this URL:|
Hayder SA, Raziq AH. The correlation of e-cadherin expression with the modified gleason score and the grade group of prostatic adenocarcinoma. Med J Babylon [serial online] 2021 [cited 2022 Aug 18];18:102-6. Available from: https://www.medjbabylon.org/text.asp?2021/18/2/102/319502
| Introduction|| |
Epithelial mesenchymal transition (EMT) is the process by which epithelial cells gain more mesenchymal features, promoting tumor invasion and metastasis. EMT is also associated with chemoresistance in many cancers. The triggering event in EMT includes changes in intercellular adhesion molecules, and downregulation of epithelial markers among which E-cadherin is a key factor.,
E-cadherin is a membrane glycoprotein that functions to maintain epithelial cell–cell adhesion through Ca2+ binding site. Loss of E-cadherin leads to disaggregation of tumor cells from one another promoting invasiveness and metastasis.,
Prostate cancer is the most common cancer in men and the second most common cause of cancer-related deaths only after lung cancer. The incidence of prostate cancer increases with advanced age, in addition to the role of environmental and genetic factors. Screening with prostate-specific antigen (PSA) has also played some role in early diagnosis and treatment of prostate cancer, as it leads to diagnoses of clinically silent disease.,
Prostate cancer has been associated with variable outcomes. Many clinicopathological factors have been used to predict the outcome, including PSA level, Gleason scoring, tumor stage, and presence of lymph node involvement.
Gleason grading system is a prognostic indicator that was introduced in the 1960s and modified in 2005, it depends on histological patterns for grading prostate cancer.,
Based on a pattern of glands, a Gleason score of 1–5 is given, the summation of the primary and the secondary patterns will give the Gleason grade. In 2014, the International Society of Urological Pathology introduced the Grade Grouping system, in which modified Gleason score 6 and below will be Grade Group I, 3 + 4 = 7 as Group II, 4 + 3 = 7 as Group III, 4 + 4 = 8 Group IV, and modified Gleason score 9 and 10 as Grade Group V.
Downregulation of E-cadherin expression is found in poorly differentiated tumors of many organs. The evidences of correlation between E-cadherin expression and various clinicopathological parameters of prostatic carcinoma are controversial. Some authors found no correlation between E-cadherin expression and age, serum PSA, tumor cell differentiation, and death from prostatic carcinoma, while others found a negative impact of E-cadherin loss on the outcome with increased mortality from this tumor.
The aim of this study is to find the correlation between E-cadherin expression and the pathological parameters gained from prostatic biopsies obtained for adenocarcinoma.
| Materials and Methods|| |
This study is a retrospective and prospective cross sectional study that was conducted on (50) paraffin blocks obtained from core biopsies of prostatic carcinoma. Paraffin blocks were retrieved from PAR Hospital in Erbil city, Iraq.
The original slides were re-evaluated, the Grade Group and the modified Gleason score were obtained for each case. Then, a section was obtained and stained for E-cadherin according to the manufacturer's procedure. Positive and negative controls were run also. E-cadherin expression was considered as normal or aberrant staining.
E-cadherin expression was considered normal when there is a full membranous staining in more than 90% of cells examined in five different high-power fields; otherwise, it was assigned as aberrant.
Then, the results were correlated to the Grade Group and the modified Gleason score. The E-cadherin staining pattern was also examined for its correlation with perineural invasion.
The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki. The privacy of the patients was kept secure by using a code for each patient instead of names. The study protocol and the subject information were reviewed and approved by a local ethics committee (Directorate of Health in Duhok City).
Chi-square was used to determine the correlation between E-cadherin staining pattern on the one hand and the modified Gleason score, Grade Group, and perineural invasion on the other hand and P < 0.5% was considered as significant.
| Results|| |
This study included 50 paraffin blocks obtained from core biopsies from patients who were proved to have prostatic adenocarcinoma. Of the included patients, 24 (48%) were in the seventh decade of life, and [Figure 1] shows the age groups of the patients. Only six patients (12%) fall in Grade Group 1, and [Figure 2] shows a microphotograph of prostatic adenocarcinoma belonging to the Grade Group 2 and [Table 1] shows the Grade Group of all the patients, and according to the modified Gleason score, most patients had high score [Table 2] and [Figure 3] shows a prostatic adenocarcinoma with a score of 5 + 4.
|Figure 1: The age of the included patients (a: 50–59 years, b: 60–69 years, c: ≥70 years)|
Click here to view
|Figure 2: Prostatic adenocarcinoma with Grade Group 2, most of the malignant glands are small and uniform with some larger glands and irregular outlines (H and E, ×100)|
Click here to view
|Figure 3: Prostatic adenocarcinoma with a score of 5 + 4, there is single-cell infiltration and cribriform glands (H and E, ×400)|
Click here to view
Regarding E-cadherin expression, 24 cases (48%) had aberrant E-cadherin expression [Figure 4], while the rest 26 cases (52%) had complete strong membranous expression [Figure 5]. [Table 3] and [Table 4] show the correlation between E-cadherin expression and the modified Gleason score and the Grade Group, respectively. Statistically, there was a significant correlation between aberrant E-cadherin expression and increasing grade according to the modified Gleason score and Grade Group with P values of 0.032% and 0.022%, respectively.
|Figure 5: Complete diffuse strong membranous staining for E-Cadherin (×40)|
Click here to view
|Table 3: The correlation between E-cadherin expression with modified Gleason score (P=0.032)|
Click here to view
|Table 4: The correlation between E-cadherin expression with Grade Group (P=0.022)|
Click here to view
In 24 patients (48%), perineural invasion was detected [Figure 6], half of them had aberrant E-cadherin expression which was statistically notsignificant when both the parameters (perineural invasion and aberrant E-cadherin expression) are tested against the modified Gleason score and the Grade Group (P = 0.71%), while vascular invasion was detected in two patients (4%). The correlation between perineural invasion and the Grade Group and the modified Gleason score is shown in [Table 5].
|Figure 6: Prostatic adenocarcinoma with circumferential perineural invasion (H and E, ×400)|
Click here to view
|Table 5: The correlation between E-cadherin expression with Grade Group and modified Gleason score in patients with perineural invasion (P=0.71)|
Click here to view
| Discussion|| |
Cadherins are key factors in maintaining cell-to-cell contact, one member of this family is E-cadherin which plays the main role in cell adhesion. Downregulation of E-cadherin is associated with a transition from epithelial to mesenchymal phenotype, which is known as EMT.
Aberrant E-cadherin expression is associated with aggressive tumors in many organs including the gastrointestinal tract and ovary.
Many studies have shown a decrease in E-cadherin in diffuse-type gastric cancer and a shorter survival periods than E-cadherin-positive cases, while in breast cancer, most invasive and in situ lobular breast carcinomas are negative for E-cadherin, thus giving E-cadherin the role of a tumor suppressor.
Aziza E. Abdelrahman et al. observed that most high-grade prostate cancer cases had heterogeneous E-cadherin expression, while majority of low-grade and benign prostatic hyperplasia (BPH) cases had a normal expression, this goes in hand with the study conducted by Umbas et al. In a study done by Sandy Figiel et al., they found that more than half of cases with modified Gleason score 8 expressed E-cadherin aberrantly and that aberrant E-cadherin expression was associated with a shorter survival rate.
In this study, it was found that there is a significant correlation between aberrant E-cadherin expression with increasing modified Gleason score (P = 0.032%) and Grade Group (P = 0.022%). Whether this aberrant expression is an independent prognostic factor or it is related to the grade of prostatic carcinoma, is a question that requires further studies.
To further emphasize the role of E-cadherin in prostate cancer progression, a group compared the expression of E-cadherin among prostatic hyperplasia cases, prostate carcinoma, and site of metastasis. They came up with similar results, as more than half of BPH cases had an intact expression, about half of cases with prostatic carcinoma expressed intact E-cadherin, while only a few metastatic cases had an intact expression.
A prospective study of 103 cases on which EMT markers were tested revealed that E-cadherin was decreased in cancer cases when compared with BPH cases, but over a period of 3 years of follow–up, they failed to see any difference in disease-free survival between cases with normal and aberrant expression.
However, Nabiha Missaoui et al. found that there was no correlation between E-cadherin expression and the clinicopathological parameters including patient age, tumor grade, and PSA level. Koksal et al. also concluded that there was no correlation between E-cadherin expression and modified Gleason score. Soler et al. reported that there was no significant correlation between E-cadherin and modified Gleason score. They attributed their results to the limited number of cases and stated that the expression of E-cadherin does not reflect the function of the protein.
These discrepant results between articles were related to differences in tissue processing, techniques of immunohistochemistry application, interpretation, and the scoring systems followed.
In this study, half of the cases with aberrant E-cadherin expression had perineural invasion, but there was no significant correlation between them (P = 0.71%) and this is consistent with the study performed by Taghrid Bengallol et al. who also failed to detect a correlation between E-cadherin expression and perineural invasion.
| Conclusion|| |
Aberrant E-cadherin expression is associated with increasing modified Gleason score and Grade Group but has no significant correlation with perineural invasion.
The authors express their great thanks and appreciation for Dr. Saman S Abdulla, a consultant pathologist in College of Dentistry – Hawler Medical University, for his kind help and contribution for the completion of this research.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hu QP, Kuang JY, Yang QK, Bian XW, Yu SC. Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. Int J Cancer 2016;138:2804-12.
Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm 2014;11:2539-52.
Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev 2014;15:9575-8.
Kang DI, Chung JI, Ha HK, Min K, Yoon J, Kim W, et al
. Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev 2013;14:6913-7.
Behnsawy HM, Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: Significance in clinicopathological outcomes following radical prostatectomy. BJU Int 2013;111:30-7.
Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
Chen N, Zhou Q. The evolving Gleason grading system. Chin J Cancer Res 2016;28:58-64.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al
. The 2014 International Society of Urological Pathology (ISUP) Consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244-52.
Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005;46:685-93.
Missaoui N, Abdelkarim SB, Mokni M, Hmissa S. prognostic factors of prostate cancer in tunisian men: Immunohistochemical study. Asian Pac J Cancer Prev 2016;17:2655.
Lazari P, Poulias H, Gakiopoulou H, Thomopoulou GH, Barbatis C, Lazaris AC. Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland. Urol Int 2013;90:109-16.
Liu GL, Yang HJ, Liu T, Lin YZ. Expression and significance of E-cadherin, N-cadherin, transforming growth factor-β1 and Twist in prostate cancer. Asian Pac J Trop Med 2014;7:76-82.
Arslan AI, Karabag S, Akgul M, Yildirim I. Immunohistochemical expression of E-cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Med Sci 2020;9:530-4.
Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci 2011;3:227-33.
Chan AO. E-cadherin in gastric cancer. World J Gastroenterol 2006;12:199-203.
Berx G, Van Roy F. The E-cadherin/catenin complex: An important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001;3:289-93.
Abdelrahman AE, Arafa SA, Ahmed RA. Prognostic value of twist-1, E-cadherin and EZH2 in prostate cancer: An immunohistochemical study. Turk Patoloji Derg 2017;1:198-210.
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al
. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K, Fromont G. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer. Hum Pathol 2017;61:26-32.
Fan L, Wang H, Xia X, Rao Y, Ma X, Ma D, et al. Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression. Oncol Lett 2012;4:1225-33.
Ipekci T, Ozden F, Unal B, Saygin C, Uzunaslan D, Ates E. Epithelial-mesenchymal transition markers β-catenin, snail, and E-cadherin do not predict disease free survival in prostate adenocarcinoma: A prospective study. Pathol Oncol Res 2015;21:1209-16.
Koksal IT, Zcan FO, Kiliçaslan I, Tefekl A. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: Correlation with pathological features. Pathology 2002;34:233-8.
Soler AP, Harner GD, Knudsen KA, McBrearty FX, Grujic E, Salazar H, et al
. Expression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology. Am J Pathol 1997;151:471-8.
Bengallol T, El-Faitori O, Sassi S, Khaial FB, El Gehani K, Buhmeida A, et al
. Expression of E-Cadherin in Prostatic Carcinoma: Prognostic Significance. J Cancer Prev Curr Res 2016;4:00119.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]